Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (ATYR) and Idexx Laboratories (IDXX)

Tipranks - Tue Apr 7, 5:38PM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on aTyr Pharma (ATYR) and Idexx Laboratories (IDXX).

Easter Sale - 70% Off TipRanks

aTyr Pharma (ATYR)

In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on aTyr Pharma. The company’s shares closed last Monday at $0.82.

According to TipRanks.com, Roy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.2% and a 32.2% success rate. Roy covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Monopar Therapeutics Inc. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for aTyr Pharma with a $7.33 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Idexx Laboratories (IDXX)

William Blair analyst Ryan Daniels maintained a Buy rating on Idexx Laboratories today. The company’s shares closed last Monday at $577.44.

According to TipRanks.com, Daniels is a 1-star analyst with an average return of -2.9% and a 34.1% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Lifestance Health Group, and Pediatrix Medical Group. ;'>

Idexx Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $764.29, implying a 35.0% upside from current levels. In a report issued on March 26, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $651.00 price target.

Read More on ATYR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.